Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Положительный терапевтический эффект применения блокатора if-каналов ивабрадина у пациента с хронической сердечной недостаточностью с сохранной фракцией выброса левого желудочка ишемического генеза и наследственной тромбофилией (клиническое наблюдение)
Положительный терапевтический эффект применения блокатора if-каналов ивабрадина у пациента с хронической сердечной недостаточностью с сохранной фракцией выброса левого желудочка ишемического генеза и наследственной тромбофилией (клиническое наблюдение)
Беленков Ю.Н., Привалова Е.В., Ильгисонис И.С. и др. Положительный терапевтический эффект применения блокатора if-каналов ивабрадина у пациента с хронической сердечной недостаточностью с сохранной фракцией выброса левого желудочка ишемического генеза и наследственной тромбофилией (клиническое наблюдение). CardioСоматика. 2019; 10 (3): 79–84. DOI: 10.26442/22217185.2019.3.190544
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Хроническая сердечная недостаточность (ХСН) является одной из ведущих причин смертности среди пациентов с заболеваниями сердечно-сосудистой системы. Современные терапевтические методы лечения пациентов с ХСН не всегда обеспечивают значимое улучшение основных промежуточных и конечных исходов. Согласно нейрогуморальной теории развития ХСН, антагонизм симпатоадреналовой системы b-адреноблокаторами (b-АБ) является патогенетически обоснованным, а препараты данной группы одни из основных в лечении ХСН. Подбор пульсурежающей терапии у больных с ХСН ишемического генеза часто может быть затруднен в связи с развитием нежелательных побочных эффектов b-АБ, их непереносимостью и/или в связи с наличием противопоказаний при тяжелой коморбидной патологии. В настоящей статье приводится клинический случай эффективного назначения препарата группы ингибиторов if-каналов ивабрадин в комбинации с b-АБ пациенту с ХСН с сохранной фракцией выброса.
Ключевые слова: хроническая сердечная недостаточность, хроническая сердечная недостаточность с сохранной фракцией выброса, ишемическая болезнь сердца, ивабрадин, частота сердечных сокращений, тахикардия.
Key words: chronic heart failure, chronic heart failure with preserved ejection fraction, coronary heart disease, ivabradine, heart rate, tachycardia.
Ключевые слова: хроническая сердечная недостаточность, хроническая сердечная недостаточность с сохранной фракцией выброса, ишемическая болезнь сердца, ивабрадин, частота сердечных сокращений, тахикардия.
________________________________________________
Key words: chronic heart failure, chronic heart failure with preserved ejection fraction, coronary heart disease, ivabradine, heart rate, tachycardia.
Полный текст
Список литературы
1. Kenworthy W, Guha K, Sharma R. The patient with left ventricular systolic dysfunction now and in the future. Br J Hosp Med (Lond) 2016; 77: 516–22. DOI: 10.1177/2040622318784556
2. Фомин И.В. и др. Распространенность хронической сердечной недостаточности в Европейской части Российской Федерации – данные ЭПОХА-ХСН. Сердечная недостаточность. 2006; 7 (1): 112–5. https://doi.org/10.15829/ 1560-4071-2016-8-7-13
[Fomin I.V. et al. Rasprostranennost' khronicheskoi serdechnoi nedostatochnosti v Evropeiskoi chasti Rossiiskoi Federatsii – dannye EPOKhA-KhSN. Serdechnaia nedostatochnost'. 2006; 7 (1): 112–5. https://doi.org/10.15829/1560-4071-2016-8-7-13 (in Russian).]
3. Агеев Ф.Т., Даниелян М.О., Мареев В.Ю. и др. Больные с хронической сердечной недостаточностью в российской амбулаторной практике: особенности контингента, диагностики и лечения (по материалам исследования ЭПОХА- О-ХСН). Сердечная недостаточность. 2004; 5 (1): 4–7.
[Ageev F.T., Danielian M.O., Mareev V.Iu. et al. Bol'nye s khronicheskoi serdechnoi nedostatochnost'iu v rossiiskoi ambulatornoi praktike: osobennosti kontingenta, diagnostiki i lecheniia (po materialam issledovaniia EPOKhA-O-KhSN). Serdechnaia nedostatochnost'. 2004; 5 (1): 4–7 (in Russian).]
4. Мареев В.Ю., Даниелян М.О., Беленков Ю.Н. От имени рабочей группы исследования ЭПОХА-О-ХСН. Сравнительная характеристика больных с ХСН в зависимости от величины ФВ по результатам Российского многоцентрового исследования ЭПОХА-О-ХСН. Сердечная недостаточность. 2006;7 (4): 164–71.
[Mareev V.Iu., Danielian M.O., Belenkov Iu.N. Ot imeni rabochei gruppy issledovaniia EPOKhA-O-KhSN. Sravnitel'naia kharakteristika bol'nykh s KhSN v zavisimosti ot velichiny FV po rezul'tatam Rossiiskogo mnogotsentrovogo issledovaniia EPOKhA-O-KhSN. Serdechnaia nedostatochnost'. 2006;7 (4): 164–71 (in Russian).]
5. EURObservational Research Programme: Regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Failure 2013; 15 (7). DOI: 10.1093/eurjhf/hft050
6. Mozzafarian D, Benjamin EJ, Go AS et al. Heart disease and stroke statistics – 2016 update: a report from the American Heart Association. Circulation 2016; 133: e38–e360. https://doi.org/10.1161/CIR.0000000000000350
7. National Institute for Health and Care Excellence. Chronic heart failure in adults: management, https://www.nice.org.uk/guidance/ cg108/resources/chronic-heart-failure-in-adultsmanagement-pdf-35109335688901 (2010, accessed 14 January 2018).
8. Cook S, Togni M, Schaub MC et al. High heart rate: a cardiovascular risk factor? Eur Heart J 2006; 27: 2387–93.
9. Fox K, Borer JS, Camm AJ et al. Resting heart rate in cardiovascular disease. J Am Coll Cardiol 2007; 50: 823–30. https://doi.org/10.1016/j.jacc.2007.04.079
10. Reil JC, Bohm M. The role of heart rate in the development of cardiovascular disease. ClinRes Cardiol2007; 96: 585–92. DOI: 10.1007/s00392-007-0537-5
11. Lechat P, Hulot JS, Escolano S et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation 2001; 103: 1428–33. https://doi.org/10.1161/01
12. Flannery G, Gehrig-Mills R, Billah B et al. Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers. Am J Cardiol 2008; 101: 865–69. DOI: 10.1016/j.amjcard.2007.11.023
13. McAlister FA, Wiebe N, Ezekowitz JA et al. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 2009; 150: 784–94. DOI: 10.7326/0003-4819-150-11-200906020-00006
14. Gloekler S, Traupe T, Stoller M et al. The effect of heart rate reduction by ivabradine on collateral function in patients with chronic stable coronary artery disease. Seiler Heart 2014; 100 (2): 160–6. DOI: 10.1136/heartjnl-2013-304880
15. Lopatin YM, Vitale C. Effect of ivabradine on central aortic blood pressure in patients with stable coronary artery disease: What do we know? IntJ Cardiol 2016; 224: 145–8. DOI: 10.1016/j.ijcard.2016.09.054
16. Fox K, Ford I, Steg PG et al. Ivabradine for patients with stable coronary artery disease and leftventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 807–16. DOI:10.1016/S0140-6736(08)61170-8
17. Tardif J-C, Ponikowski P, Kahan T on behalf of the ASSOCIATE investigators. Effects of ivabradine in patients with stable angina receiving beta-blockers according to baseline heart rate: an analysis of the ASSOCIATE study. Int J Cardiol 2013; 168; 789–94. http://dx.doi.org/10.1016/j.ijcard.2012.10.011
18. Swedberg K, Komajda M, Böhm M et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376 (9744): 875–85. DOI: 10.1016/S0140-6736(10)61198-1
19. Ponikowski P, Voors AA, Anker SD et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016; 18 (8): 891–975. DOI: 10.1002/ejhf.592
2. Fomin I.V. et al. Rasprostranennost' khronicheskoi serdechnoi nedostatochnosti v Evropeiskoi chasti Rossiiskoi Federatsii – dannye EPOKhA-KhSN. Serdechnaia nedostatochnost'. 2006; 7 (1): 112–5. https://doi.org/10.15829/1560-4071-2016-8-7-13 (in Russian).
3. Ageev F.T., Danielian M.O., Mareev V.Iu. et al. Bol'nye s khronicheskoi serdechnoi nedostatochnost'iu v rossiiskoi ambulatornoi praktike: osobennosti kontingenta, diagnostiki i lecheniia (po materialam issledovaniia EPOKhA-O-KhSN). Serdechnaia nedostatochnost'. 2004; 5 (1): 4–7 (in Russian).
4. Mareev V.Iu., Danielian M.O., Belenkov Iu.N. Ot imeni rabochei gruppy issledovaniia EPOKhA-O-KhSN. Sravnitel'naia kharakteristika bol'nykh s KhSN v zavisimosti ot velichiny FV po rezul'tatam Rossiiskogo mnogotsentrovogo issledovaniia EPOKhA-O-KhSN. Serdechnaia nedostatochnost'. 2006;7 (4): 164–71 (in Russian).
5. EURObservational Research Programme: Regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Failure 2013; 15 (7). DOI: 10.1093/eurjhf/hft050
6. Mozzafarian D, Benjamin EJ, Go AS et al. Heart disease and stroke statistics – 2016 update: a report from the American Heart Association. Circulation 2016; 133: e38–e360. https://doi.org/10.1161/CIR.0000000000000350
7. National Institute for Health and Care Excellence. Chronic heart failure in adults: management, https://www.nice.org.uk/guidance/ cg108/resources/chronic-heart-failure-in-adultsmanagement-pdf-35109335688901 (2010, accessed 14 January 2018).
8. Cook S, Togni M, Schaub MC et al. High heart rate: a cardiovascular risk factor? Eur Heart J 2006; 27: 2387–93.
9. Fox K, Borer JS, Camm AJ et al. Resting heart rate in cardiovascular disease. J Am Coll Cardiol 2007; 50: 823–30. https://doi.org/10.1016/j.jacc.2007.04.079
10. Reil JC, Bohm M. The role of heart rate in the development of cardiovascular disease. ClinRes Cardiol2007; 96: 585–92. DOI: 10.1007/s00392-007-0537-5
11. Lechat P, Hulot JS, Escolano S et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation 2001; 103: 1428–33. https://doi.org/10.1161/01
12. Flannery G, Gehrig-Mills R, Billah B et al. Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers. Am J Cardiol 2008; 101: 865–69. DOI: 10.1016/j.amjcard.2007.11.023
13. McAlister FA, Wiebe N, Ezekowitz JA et al. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 2009; 150: 784–94. DOI: 10.7326/0003-4819-150-11-200906020-00006
14. Gloekler S, Traupe T, Stoller M et al. The effect of heart rate reduction by ivabradine on collateral function in patients with chronic stable coronary artery disease. Seiler Heart 2014; 100 (2): 160–6. DOI: 10.1136/heartjnl-2013-304880
15. Lopatin YM, Vitale C. Effect of ivabradine on central aortic blood pressure in patients with stable coronary artery disease: What do we know? IntJ Cardiol 2016; 224: 145–8. DOI: 10.1016/j.ijcard.2016.09.054
16. Fox K, Ford I, Steg PG et al. Ivabradine for patients with stable coronary artery disease and leftventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 807–16. DOI:10.1016/S0140-6736(08)61170-8
17. Tardif J-C, Ponikowski P, Kahan T on behalf of the ASSOCIATE investigators. Effects of ivabradine in patients with stable angina receiving beta-blockers according to baseline heart rate: an analysis of the ASSOCIATE study. Int J Cardiol 2013; 168; 789–94. http://dx.doi.org/10.1016/j.ijcard.2012.10.011
18. Swedberg K, Komajda M, Böhm M et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376 (9744): 875–85. DOI: 10.1016/S0140-6736(10)61198-1
19. Ponikowski P, Voors AA, Anker SD et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016; 18 (8): 891–975. DOI: 10.1002/ejhf.592
2. Фомин И.В. и др. Распространенность хронической сердечной недостаточности в Европейской части Российской Федерации – данные ЭПОХА-ХСН. Сердечная недостаточность. 2006; 7 (1): 112–5. https://doi.org/10.15829/ 1560-4071-2016-8-7-13
[Fomin I.V. et al. Rasprostranennost' khronicheskoi serdechnoi nedostatochnosti v Evropeiskoi chasti Rossiiskoi Federatsii – dannye EPOKhA-KhSN. Serdechnaia nedostatochnost'. 2006; 7 (1): 112–5. https://doi.org/10.15829/1560-4071-2016-8-7-13 (in Russian).]
3. Агеев Ф.Т., Даниелян М.О., Мареев В.Ю. и др. Больные с хронической сердечной недостаточностью в российской амбулаторной практике: особенности контингента, диагностики и лечения (по материалам исследования ЭПОХА- О-ХСН). Сердечная недостаточность. 2004; 5 (1): 4–7.
[Ageev F.T., Danielian M.O., Mareev V.Iu. et al. Bol'nye s khronicheskoi serdechnoi nedostatochnost'iu v rossiiskoi ambulatornoi praktike: osobennosti kontingenta, diagnostiki i lecheniia (po materialam issledovaniia EPOKhA-O-KhSN). Serdechnaia nedostatochnost'. 2004; 5 (1): 4–7 (in Russian).]
4. Мареев В.Ю., Даниелян М.О., Беленков Ю.Н. От имени рабочей группы исследования ЭПОХА-О-ХСН. Сравнительная характеристика больных с ХСН в зависимости от величины ФВ по результатам Российского многоцентрового исследования ЭПОХА-О-ХСН. Сердечная недостаточность. 2006;7 (4): 164–71.
[Mareev V.Iu., Danielian M.O., Belenkov Iu.N. Ot imeni rabochei gruppy issledovaniia EPOKhA-O-KhSN. Sravnitel'naia kharakteristika bol'nykh s KhSN v zavisimosti ot velichiny FV po rezul'tatam Rossiiskogo mnogotsentrovogo issledovaniia EPOKhA-O-KhSN. Serdechnaia nedostatochnost'. 2006;7 (4): 164–71 (in Russian).]
5. EURObservational Research Programme: Regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Failure 2013; 15 (7). DOI: 10.1093/eurjhf/hft050
6. Mozzafarian D, Benjamin EJ, Go AS et al. Heart disease and stroke statistics – 2016 update: a report from the American Heart Association. Circulation 2016; 133: e38–e360. https://doi.org/10.1161/CIR.0000000000000350
7. National Institute for Health and Care Excellence. Chronic heart failure in adults: management, https://www.nice.org.uk/guidance/ cg108/resources/chronic-heart-failure-in-adultsmanagement-pdf-35109335688901 (2010, accessed 14 January 2018).
8. Cook S, Togni M, Schaub MC et al. High heart rate: a cardiovascular risk factor? Eur Heart J 2006; 27: 2387–93.
9. Fox K, Borer JS, Camm AJ et al. Resting heart rate in cardiovascular disease. J Am Coll Cardiol 2007; 50: 823–30. https://doi.org/10.1016/j.jacc.2007.04.079
10. Reil JC, Bohm M. The role of heart rate in the development of cardiovascular disease. ClinRes Cardiol2007; 96: 585–92. DOI: 10.1007/s00392-007-0537-5
11. Lechat P, Hulot JS, Escolano S et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation 2001; 103: 1428–33. https://doi.org/10.1161/01
12. Flannery G, Gehrig-Mills R, Billah B et al. Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers. Am J Cardiol 2008; 101: 865–69. DOI: 10.1016/j.amjcard.2007.11.023
13. McAlister FA, Wiebe N, Ezekowitz JA et al. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 2009; 150: 784–94. DOI: 10.7326/0003-4819-150-11-200906020-00006
14. Gloekler S, Traupe T, Stoller M et al. The effect of heart rate reduction by ivabradine on collateral function in patients with chronic stable coronary artery disease. Seiler Heart 2014; 100 (2): 160–6. DOI: 10.1136/heartjnl-2013-304880
15. Lopatin YM, Vitale C. Effect of ivabradine on central aortic blood pressure in patients with stable coronary artery disease: What do we know? IntJ Cardiol 2016; 224: 145–8. DOI: 10.1016/j.ijcard.2016.09.054
16. Fox K, Ford I, Steg PG et al. Ivabradine for patients with stable coronary artery disease and leftventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 807–16. DOI:10.1016/S0140-6736(08)61170-8
17. Tardif J-C, Ponikowski P, Kahan T on behalf of the ASSOCIATE investigators. Effects of ivabradine in patients with stable angina receiving beta-blockers according to baseline heart rate: an analysis of the ASSOCIATE study. Int J Cardiol 2013; 168; 789–94. http://dx.doi.org/10.1016/j.ijcard.2012.10.011
18. Swedberg K, Komajda M, Böhm M et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376 (9744): 875–85. DOI: 10.1016/S0140-6736(10)61198-1
19. Ponikowski P, Voors AA, Anker SD et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016; 18 (8): 891–975. DOI: 10.1002/ejhf.592
________________________________________________
2. Fomin I.V. et al. Rasprostranennost' khronicheskoi serdechnoi nedostatochnosti v Evropeiskoi chasti Rossiiskoi Federatsii – dannye EPOKhA-KhSN. Serdechnaia nedostatochnost'. 2006; 7 (1): 112–5. https://doi.org/10.15829/1560-4071-2016-8-7-13 (in Russian).
3. Ageev F.T., Danielian M.O., Mareev V.Iu. et al. Bol'nye s khronicheskoi serdechnoi nedostatochnost'iu v rossiiskoi ambulatornoi praktike: osobennosti kontingenta, diagnostiki i lecheniia (po materialam issledovaniia EPOKhA-O-KhSN). Serdechnaia nedostatochnost'. 2004; 5 (1): 4–7 (in Russian).
4. Mareev V.Iu., Danielian M.O., Belenkov Iu.N. Ot imeni rabochei gruppy issledovaniia EPOKhA-O-KhSN. Sravnitel'naia kharakteristika bol'nykh s KhSN v zavisimosti ot velichiny FV po rezul'tatam Rossiiskogo mnogotsentrovogo issledovaniia EPOKhA-O-KhSN. Serdechnaia nedostatochnost'. 2006;7 (4): 164–71 (in Russian).
5. EURObservational Research Programme: Regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Failure 2013; 15 (7). DOI: 10.1093/eurjhf/hft050
6. Mozzafarian D, Benjamin EJ, Go AS et al. Heart disease and stroke statistics – 2016 update: a report from the American Heart Association. Circulation 2016; 133: e38–e360. https://doi.org/10.1161/CIR.0000000000000350
7. National Institute for Health and Care Excellence. Chronic heart failure in adults: management, https://www.nice.org.uk/guidance/ cg108/resources/chronic-heart-failure-in-adultsmanagement-pdf-35109335688901 (2010, accessed 14 January 2018).
8. Cook S, Togni M, Schaub MC et al. High heart rate: a cardiovascular risk factor? Eur Heart J 2006; 27: 2387–93.
9. Fox K, Borer JS, Camm AJ et al. Resting heart rate in cardiovascular disease. J Am Coll Cardiol 2007; 50: 823–30. https://doi.org/10.1016/j.jacc.2007.04.079
10. Reil JC, Bohm M. The role of heart rate in the development of cardiovascular disease. ClinRes Cardiol2007; 96: 585–92. DOI: 10.1007/s00392-007-0537-5
11. Lechat P, Hulot JS, Escolano S et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation 2001; 103: 1428–33. https://doi.org/10.1161/01
12. Flannery G, Gehrig-Mills R, Billah B et al. Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers. Am J Cardiol 2008; 101: 865–69. DOI: 10.1016/j.amjcard.2007.11.023
13. McAlister FA, Wiebe N, Ezekowitz JA et al. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 2009; 150: 784–94. DOI: 10.7326/0003-4819-150-11-200906020-00006
14. Gloekler S, Traupe T, Stoller M et al. The effect of heart rate reduction by ivabradine on collateral function in patients with chronic stable coronary artery disease. Seiler Heart 2014; 100 (2): 160–6. DOI: 10.1136/heartjnl-2013-304880
15. Lopatin YM, Vitale C. Effect of ivabradine on central aortic blood pressure in patients with stable coronary artery disease: What do we know? IntJ Cardiol 2016; 224: 145–8. DOI: 10.1016/j.ijcard.2016.09.054
16. Fox K, Ford I, Steg PG et al. Ivabradine for patients with stable coronary artery disease and leftventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 807–16. DOI:10.1016/S0140-6736(08)61170-8
17. Tardif J-C, Ponikowski P, Kahan T on behalf of the ASSOCIATE investigators. Effects of ivabradine in patients with stable angina receiving beta-blockers according to baseline heart rate: an analysis of the ASSOCIATE study. Int J Cardiol 2013; 168; 789–94. http://dx.doi.org/10.1016/j.ijcard.2012.10.011
18. Swedberg K, Komajda M, Böhm M et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376 (9744): 875–85. DOI: 10.1016/S0140-6736(10)61198-1
19. Ponikowski P, Voors AA, Anker SD et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016; 18 (8): 891–975. DOI: 10.1002/ejhf.592
Авторы
Ю.Н. Беленков, Е.В. Привалова, И.С. Ильгисонис, Ю.И. Найманн, А.В. Жито*
ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия
*azhito77@mail.ru
Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
*azhito77@mail.ru
ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия
*azhito77@mail.ru
________________________________________________
Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
*azhito77@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.